Meeting
2019 Gastrointestinal Cancers Symposium
MACC1 expression as a candidate prognostic biomarker in colorectal cancer patients receiving adjuvant oxaliplatin-based therapy.
Authors
Lynn Katherine Symonds
University of Washington, Seattle, WA
Lynn Katherine Symonds , Kelsey K. Baker , Mary Weber Redman , Lisa Koch , Kelly Carter , Ming Yu , Ralph Wirtz , Christos Poulios , George E. Pentheroudakis , George Papaxoinis , Dimitrios G. Pectasides , Konstantine T. Kalogeras , George Fountzilas , William M. Grady , Stacey Cohen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 567)
DOI
10.1200/JCO.2019.37.4_suppl.567
Abstract #
567
Poster Bd #
G10
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Evaluation of the CpG island methylator phenotype as a predictive biomarker for adjuvant oxaliplatin-based chemotherapy in colorectal cancer.
First Author: Stacey Shiovitz
Poster
2014 Gastrointestinal Cancers Symposium
The safety of chemotherapy for colorectal cancer patients with hepatitis C virus infection.
First Author: Kenji Tomizawa
Poster
2024 ASCO Annual Meeting
GEMINI-Gastric: A phase 2 study of novel treatment combinations in patients with locally advanced unresectable or metastatic gastric cancers.
First Author: Lin Shen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
First Author: Meng Wang